Repligen Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance

REPLIGEN CORP (RGEN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance • Third quarter revenue of $209 million, a year-over-year increase of 11% as r

Event · Earnings
Also in this documentGuidance · raise · $844M–$852M

Facts are quoted from the filing text and checked against it.

Original reporting
Published Oct 27, 2026, 11:04 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 11:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$RGEN
Bullish
high confidence
Mentioned
$RGEN
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$RGENBullishHigh
01

Why it matters

The revenue guidance increase signals stronger demand and successful acquisition, likely supporting a price rally.

02

Market read

First‑report earnings and guidance lift for a mid‑cap biotech, offering a clear trading catalyst.

03

What to watch

Potential impact of foreign currency fluctuations and integration costs of BioLife

Relevance 8/10Novelty 8/10Timing: after-hours release
AlphAI · Earnings readRGEN · Q3 2026 · ended September 30, 2026

Repligen Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance

✓Solid quarter

Q3 revenue increased 11% as reported and 12.5% organic, adjusted operating income and adjusted EPS increased, and the Company raised FY 2026 revenue guidance. GAAP results were affected by a $41,242 intangible asset impairment charge, resulting in a Q3 GAAP net loss of $ (38,432) and GAAP diluted loss per share of $ (0.68).

Revenue
$209M
11 % y/y
Gross margin · GAAP
53.0%
EPS · non-GAAP
$ 0.53
FY 2026 outlook
$844M - $852M
GM 53.7% - 54.2%

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Q3 2026 total revenueGAAP$209.3M–11 %
Q3 2026 product revenueGAAP$209.3M––
Q3 2026 royalty and other revenueGAAP44––
Q3 2026 organic revenue growthnon-GAAP12 %––
Q3 2026 GAAP gross marginGAAP53.0%––
Q3 2026 adjusted gross marginnon-GAAP53.0%––
Q3 2026 loss from operationsGAAP−$29.55M––
Q3 2026 GAAP operating (loss) EBIT marginGAAP(14.1) %––
Q3 2026 adjusted income from operationsnon-GAAP$33.29M––
Q3 2026 adjusted operating (EBIT) marginnon-GAAP15.9 %––
Q3 2026 net (loss) incomeGAAP−$38.43M––
Q3 2026 GAAP net (loss) income marginGAAP(18.4) %––
Q3 2026 adjusted net incomenon-GAAP$29.88M––
Q3 2026 adjusted net income marginnon-GAAP14.3 %––
Q3 2026 diluted (loss) EPSGAAP$ (0.68)––
Q3 2026 adjusted EPS - dilutednon-GAAP$ 0.53––
Q3 2026 adjusted EBITDAnon-GAAP$43.84M––
Q3 2026 adjusted EBITDA marginnon-GAAP20.9 %––
Nine months ended September 30, 2026 total revenueGAAP$607.7M–13 %
Nine months ended September 30, 2026 product revenueGAAP$607.6M––
Nine months ended September 30, 2026 royalty and other revenueGAAP131––
Nine months ended September 30, 2026 organic revenue growthnon-GAAP12 %––
Nine months ended September 30, 2026 GAAP gross marginGAAP54.2%––
Nine months ended September 30, 2026 adjusted gross marginnon-GAAP54.1%––
Nine months ended September 30, 2026 income from operationsGAAP$ 370––
Nine months ended September 30, 2026 adjusted income from operationsnon-GAAP$97.20M––
Nine months ended September 30, 2026 net (loss) incomeGAAP−$25.09M––
Nine months ended September 30, 2026 adjusted net incomenon-GAAP$87.81M––
Nine months ended September 30, 2026 diluted (loss) EPSGAAP$ (0.44)––
Nine months ended September 30, 2026 adjusted EPS - dilutednon-GAAP$ 1.55––
Nine months ended September 30, 2026 adjusted EBITDAnon-GAAP$127.6M––
Nine months ended September 30, 2026 adjusted EBITDA marginnon-GAAP21.0 %––
Nine months ended September 30, 2026 cash provided by operating activitiesGAAP104,160––
Nine months ended September 30, 2026 purchases of property, plant and equipmentGAAP(14,992)––
Cash and cash equivalents at September 30, 2026GAAP$727.0M––
Marketable securities at September 30, 2026GAAP136,019––
Convertible Senior Notes due 2028, net at September 30, 2026GAAP555,596––

FY 2026 outlook

  • Revenue$844M - $852M
  • Gross margin53.7% - 54.2%
  • Tax rate~22%
  • NoteAdjusted (non-GAAP) reported growth: 14.5% - 15.5%
  • NoteAdjusted (non-GAAP) organic growth: 12% - 13%
  • NoteAdjusted (non-GAAP) income from operations: $135M - $139M
  • NoteAdjusted (non-GAAP) operating margin: 16.0% - 16.3%
  • NoteAdjusted (non-GAAP) other income (expense): ~$18M
  • NoteAdjusted (non-GAAP) EBITDA margin: ~21%
  • NoteAdjusted (non-GAAP) net income: $119M - $122M
  • NoteAdjusted (non-GAAP) earnings per share - diluted: $2.05 - $2.09
  • NoteTotal reported revenue guidance reflects a neutral impact from foreign currency and an approximately 2.5 point tailwind from inorganic growth primarily from the BioLife acquisition net of the divestiture of Polymem.

What drove it

  • Q3 reported revenue increased 11% and organic revenue growth was 12.5%.
  • Management cited continued strength across its diversified portfolio, healthy trends in consumables and services, and a growing capital equipment order book.
  • The BioLife acquisition closed on October 6, 2026 and is included in FY 2026 guidance from the closing date.
  • Adjusted operating (EBIT) margin was 15.9 %, compared with 14.2 % in Q3 2025.
  • Q3 adjusted EBITDA margin was 20.9 %, compared with 19.0 % in Q3 2025.

Concerns

  • Q3 GAAP loss from operations was $ (29,546), compared to income from operations of $ 16,825.
  • Q3 net loss was $ (38,432), compared to net income of $ 14,911.
  • Q3 intangible asset impairment charges were 41,242, compared to —.
  • The Company cited risks related to successful BioLife integration and realizing expected acquisition benefits and synergies.
  • The Company cited risks that demand for its products could decline and that tariffs could affect its business.

What to watch

  • Execution of BioLife integration and realization of expected operating expense synergies.
  • Consumables and services demand trends and capital equipment order-book development.
  • Delivery against FY 2026 adjusted revenue guidance of $844M - $852M and adjusted operating margin guidance of 16.0% - 16.3%.
  • The impact of the $41,242 Q3 intangible asset impairment charge on GAAP results.

Balance sheet and cash flow

  • Cash, cash equivalents and marketable securities at September 30, 2026, were $863 million, compared to $768 million at December 31, 2025.
  • Cash and cash equivalents were $ 726,960 at September 30, 2026, compared to $ 566,021 at December 31, 2025.
  • Marketable securities were 136,019 at September 30, 2026, compared to 201,607 at December 31, 2025.
  • Convertible Senior Notes due 2028, net were 555,596 at September 30, 2026, compared to 542,213 at December 31, 2025.
  • Nine months ended September 30, 2026 total cash provided by operating activities was 104,160, compared to 91,713.
  • Nine months ended September 30, 2026 purchases of property, plant and equipment were (14,992), compared to (15,366).
  • Nine months ended September 30, 2026 net increase in cash, cash equivalents and restricted cash was 162,989, compared to net decrease of (8,608).

Analysis

Repligen reported Q3 2026 total revenue of $ 209,314, compared with $ 188,805 in Q3 2025. Reported revenue growth was 11 %, while organic revenue growth was 12 %. Management attributed performance to continued strength across its diversified portfolio, healthy consumables and services trends, and a growing capital equipment order book. Product revenue was $ 209,270, compared with $ 188,766, while royalty and other revenue was 44, compared with 39.

Profitability diverged sharply between GAAP and adjusted measures. Q3 GAAP loss from operations was $ (29,546), versus income from operations of $ 16,825, and GAAP net loss was $ (38,432), versus net income of $ 14,911. The release identifies a $41,242 intangible asset impairment charge as the primary driver of the operating loss. By contrast, adjusted income from operations was $ 33,288, compared with $ 26,770, and adjusted EPS was $ 0.53, compared with $ 0.46. Adjusted operating margin was 15.9 %, compared with 14.2 %, and adjusted EBITDA margin was 20.9 %, compared with 19.0 %.

For the nine months ended September 30, 2026, total revenue was $ 607,697, compared with $ 540,343, with reported revenue growth of 13 % and organic revenue growth of 12 %. GAAP income from operations was $ 370, compared with $ 37,299, while adjusted income from operations was $ 97,196, compared with $ 72,086. Nine-month operating cash flow was 104,160, compared with 91,713. Cash, cash equivalents and marketable securities were $863 million at September 30, 2026, compared with $768 million at December 31, 2025, while Convertible Senior Notes due 2028, net were 555,596.

The Company raised FY 2026 adjusted total reported revenue guidance to $844M - $852M, representing reported growth of 14.5% - 15.5%, and guided organic growth of 12% - 13%. The guide includes BioLife Solutions from its October 6, 2026 closing date. Repligen expects adjusted gross margin of 53.7% - 54.2%, adjusted income from operations of $135M - $139M, adjusted operating margin of 16.0% - 16.3%, adjusted net income of $119M - $122M, and adjusted diluted EPS of $2.05 - $2.09. The release states that inorganic growth, primarily from BioLife net of the Polymem divestiture, provides an approximately 2.5 point tailwind to total reported revenue guidance.

Management, verbatim

We delivered a record third quarter, with $209 million in revenue and 12.5% organic growth, driven by continued strength across our diversified portfolio. End-market demand continues to improve, with healthy trends in consumables and services complemented by a growing capital equipment order book.

Olivier Loeillot, President and Chief Executive Officer of Repligen

The completion of the BioLife acquisition in October marks a significant milestone for Repligen, and integration is progressing well. Early customer feedback has been very encouraging, and we have already taken actions to realize a sizable portion of our expected operating expense synergies. Our strong year-to-date performance, continued order momentum and the addition of BioLife give us confidence to raise our full-year guidance again.

Olivier Loeillot, President and Chief Executive Officer of Repligen

Not in the filing

stated, not guessed
  • Previous outlook was not provided; comparison of actual results with prior guidance is unavailable.
  • No reportable operating segment revenue was provided.
  • Free cash flow was not reported.
  • Q3 operating cash flow was not reported.
  • Capital-return activity, including share repurchases and dividends, was not reported.
  • FY 2026 GAAP guidance was not provided.
  • FY 2026 operating-expense guidance was not provided.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

Repligen (NASDAQ:RGEN) filed an 8‑K reporting Q3 2026 results and updated FY26 guidance.

Company-level read

Ticker impact

$RGENBullishHigh confidence
Context

issued guidance raising FY26 revenue to $844-$852M after reporting Q3 results

Expected impact

likely upward pressure as investors price in higher revenue outlook

Evidence & confidence

Guidance lift suggests improved demand and successful BioLife acquisition, supporting a bullish bias.

Market effects

bioprocessing sector may see modest uplift from Repligen's growth signal

U.S. biotech investors could adjust exposure ahead of earnings season

limited to niche biotech investors, no broad market effect

Counterpoint

Guidance raise may already be priced in; risk of execution delays from integration

Key entities

  • Repligen Corporation

    Bioprocessing firm reporting earnings and guidance

  • BioLife Solutions

    Acquired by Repligen to expand cell‑therapy platform

Every RGEN earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

$RGENMed

Stifel reiterates Buy on Repligen stock, keeps $207 target

Stifel maintained a Buy rating on Repligen (NASDAQ:RGEN) with a $207 price target, citing upside from the Biolife acquisition and strong 2027 outlook. The stock has risen 51% in six months. Repligen reported Q3 2026 earnings of $0.53 per share, beating estimates, with revenue up 11% YoY. Canaccord Genuity kept a Hold rating with a $180 target.

$RGENHighAI 8/10

RGEN Q3 deep dive: margin headwinds and BioLife integration shape improved full-year outlook

Repligen reported Q3 revenue of $209.3M, beating estimates, with adjusted EPS of $0.53 and adjusted EBITDA of $43.84M. The company raised full-year revenue guidance to $848M and adjusted EPS to $2.07. Growth was driven by proteins and chromatography segments, while filtration revenue declined. The BioLife acquisition is expected to drive future growth and margin expansion.

$RGENMed

Repligen Announces $1 Bln Convertible Notes Offering To Extend Debt Maturity

Repligen Corp. (RGEN) announced a $1 billion convertible notes offering due 2031. $541.4 million will exchange existing 2028 notes, while $458.6 million will be issued for cash. The new notes have a 20% premium conversion price. Proceeds will fund share repurchases, working capital, and potential acquisitions. The deal extends debt maturity and reduces interest expenses, benefiting EPS from 2026.